NCT06829641

Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC

A Multicenter Real-World Data Pooled Analysis: The Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: West China Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes in Stage III (cTNM-IIIB/IIIC) Non-Small Cell Lung Cancer.Patients meeting inclusion and exclusion criteria were enrolled, with treatment modalities and clinical outcomes of stage III non-small cell lung cancer (NSCLC) patients from multiple tertiary hospitals in real-world settings since August 2020 being collected and analyzed.

Detailed description

Key Inclusion Population： Stage IIIB/IIIC NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system.Patients were negative for EGFR-sensitive mutations or ALK/ROS1 fusion alterations. No prior chemotherapy, radiotherapy, surgical intervention, or immunotherapy had been administered.ECOG PS scores of the enrolled patients ranged from 0 to 2. Neoadjuvant/Induction Therapy Regimen: Tislelizumab combined with platinum-based doublet chemotherapy was administered for at Least Two Cycles , followed by surgical resection or other therapeutic interventions (e.g., radiotherapy/chemotherapy). Real-world clinical outcomes were collected and analyzed based on patients' subsequent treatment pathways.Clinical Stage IIIB-IIIC Non-Small Cell Lung Cancer (AJCC 8th Edition Staging); ECOG PS Score 0-2 Retrospective data collection was conducted for cases prior to site initiation, while prospective collection was implemented for post-initiation cases. Collected parameters include: 1. Patient clinical characteristics 2. Treatment patterns 3. Treatment compliance 4. Safety profiles 5. Event-free survival (EFS) and overall survival (OS) tracking

Conditions

• NSCLC Stage IIIB, NSCLC Stage IIIC

Interventions

Type	Name	Description
PROCEDURE	Tislelizumab Combined with Chemotherapy,	Tislelizumab Combined with Chemotherapy as Induction Therapy

Timeline

• Start date: 2025-08-09
• Primary completion: 2025-12-01
• Completion: 2026-12-01
• First posted: 2025-02-17
• Last updated: 2025-06-27